Takeda Pharmaceutical Co Ltd
TSE:4502
Takeda Pharmaceutical Co Ltd
TSE:4502
Price:
4 143 JPY
-0.24%
Market Closed
Updated:
May 2, 2024
P/FCFE
Price to FCFE
Price to FCFE
-44.7
Current
-17.4
Median
23.2
Industry
Lower
than median
Lower
than industry value
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
P/FCFE
=-44.7
Market Cap
/
6.5T
FCFE
-145.3B
All Countries
| Market Cap | P/FCFE | ||||
|---|---|---|---|---|---|
| JP |
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
6.5T JPY | -44.7 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -40 845 137.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
737.4B USD | 142.5 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 58.7 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 2 143.3 | |
| JP |
|
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | -3 381.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
363.9B USD | 29.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
326.1B USD | 25.7 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
188.7B GBP | 53.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182B CHF | 21.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
175.9B CHF | 17.6 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A
You don't have any saved screeners yet
